Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation.
Yanhua YangSuxia GuoZiyao HuangChunhua DengLihua ChenGuoxiang ZhouZhengwei JianRuping HeZhichao HuangYongzhao YaoJiongbin LuZhiwen HuaYuli HuangPublished in: Cardiology research and practice (2020)
In HFpEF patients associated with AF, beta-blocker treatment is associated with significantly lower all-cause mortality, but it increased the risk of rehospitalization due to heart failure.
Keyphrases
- end stage renal disease
- heart failure
- atrial fibrillation
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- stem cells
- patient reported outcomes
- cardiovascular disease
- percutaneous coronary intervention
- acute coronary syndrome
- bone marrow
- left atrial appendage
- cell therapy
- angiotensin ii